News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Iran rejected a U.S. ceasefire offer and kept the Strait of Hormuz closed as strikes and missile interceptions continued, keeping oil risks elevated.
  • Markets are muted as investors await a U.S. deadline on Iran talks, with crude prices up and risk appetite subdued ahead of European PMIs.
  • President Trump signaled he may delay strikes if diplomacy advances but could issue final orders as early as Tuesday evening.
  • Samsung forecast Q1 operating profit more than eightfold year-on-year, driven by AI-memory chip demand, lifting semiconductor revenue prospects.
  • U.S. Vice President Vance is visiting Hungary to publicly back Prime Minister Orban ahead of a tight April 12 parliamentary vote.
  • Australia's most decorated living soldier was arrested and will face five counts of war-crime murder over alleged killings of detained, unarmed individuals.

Latest Articles

Intellia Shares Jump After FDA Removes Hold on MAGNITUDE-2 Phase 3 Trial

Intellia Shares Jump After FDA Removes Hold on MAGNITUDE-2 Phase 3 Trial

Intellia Therapeutics saw its stock rise sharply after the FDA lifted a clinical hold on the company’s MAGNITUDE-2 Phase 3 study of nexiguran ziclumeran (nex-z) for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). The removal of the hold allows patient enrollment to restart and prompts a modest increase in the trial's target siz…

Scotiabank Cuts Datadog Price Target to $180, Keeps Sector Outperform

Scotiabank Cuts Datadog Price Target to $180, Keeps Sector Outperform

Scotiabank has reduced its 12-month price target on Datadog to $180 from $217 while retaining a Sector Outperform rating. The bank’s fieldwork points to significant revenue exposure to OpenAI and anticipates stronger top-line growth in 2026 than management guidance. Multiple other brokerages have issued recent positive notes and price targets, refl…

TD Cowen Survey Sees Strong Residential Solar Momentum Heading Into 2026

TD Cowen Survey Sees Strong Residential Solar Momentum Heading Into 2026

TD Cowen's latest solar industry survey points to a better-than-expected fourth quarter in 2025 for the U.S. residential solar market and an optimistic demand outlook for 2026. The report underscores rising storage attachment rates, a shift toward prepaid lease products after the 25D tax credit elimination, and potential share gains for firms with …

TD Cowen Lifts Baker Hughes Price Target to $64 After Strong Q4 Results

TD Cowen Lifts Baker Hughes Price Target to $64 After Strong Q4 Results

TD Cowen increased its price target on Baker Hughes to $64 from $55 while retaining a Buy rating following stronger-than-expected fourth-quarter EBITDA and guidance that matched forecasts. The firm highlighted outperformance versus the Oil Services ETF, solid order trends, and healthy free cash flow as underpinning the move. Multiple peers have als…

Piper Sandler Cuts Roblox Price Target to $125, Keeps Overweight Rating

Piper Sandler Cuts Roblox Price Target to $125, Keeps Overweight Rating

Piper Sandler lowered its price target on Roblox Corp. to $125 from $180 while keeping an Overweight rating, citing the need for more conservative estimates beginning in the second half of 2027. The firm projects robust near-term user and bookings growth but has reduced fiscal 2027 and 2028 bookings forecasts. Other broker views on Roblox vary, wit…

UBS Sees Copper in Consolidation but Expects Prices to Resume Uptrend

UBS Sees Copper in Consolidation but Expects Prices to Resume Uptrend

Copper has entered a consolidation phase near $13,000 per metric ton after a strong run-up, with higher prices dampening Chinese demand and rising inventories applying short-term pressure. UBS strategists point to tariff-related risks and ongoing mine supply disruptions as key supports for elevated prices, while noting seasonal and speculative dyna…

Nebius: Capacity Is the Story, Not the Candle

Nebius: Capacity Is the Story, Not the Candle

Nebius (NBIS) is acting like a classic AI infrastructure momentum name: headline-driven volatility on top of a simpler underlying engine - demand for GPU capacity. With shares back near a key support zone around the mid-$90s and short interest elevated, the risk-reward favors a defined long trade as long as $91 support holds. This is not a ‘sleep w…

RBC Keeps Regeneron Price Target at $745, Flags 2026 Competitive Risks

RBC Keeps Regeneron Price Target at $745, Flags 2026 Competitive Risks

RBC Capital retained its Sector Perform rating and $745 price objective on Regeneron Pharmaceuticals in a research note published Tuesday. The firm emphasized 2026 as a year when emerging competitors could meaningfully affect Regeneron’s core franchises, even as several other analysts updated their outlooks after the company’s Eylea prerelease and …

RBC Sticks With Outperform on IBM, Cites Long-Term Cloud and AI Exposure

RBC Sticks With Outperform on IBM, Cites Long-Term Cloud and AI Exposure

RBC Capital has reiterated an Outperform rating and a $350 price target on IBM, highlighting confidence in the company’s positioning in hybrid cloud and artificial intelligence despite recent valuation and software execution questions. Investors will be focused on IBM’s January 28 earnings report and software revenue components, including managemen…